A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials-A Simulation Study.

Büsch CA, Krisam J, Kieser M

Open source

DOI
10.1016/j.jval.2022.05.015
Published
2022 Nov
Container
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jval.2022.05.015,
  title = {A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials-A Simulation Study.},
  author = {Büsch CA and Krisam J and Kieser M},
  year = {2022},
  journal = {Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  doi = {10.1016/j.jval.2022.05.015},
  url = {https://doi.org/10.1016/j.jval.2022.05.015}
}

RIS

TY  - JOUR
TI  - A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials-A Simulation Study.
AU  - Büsch CA
AU  - Krisam J
AU  - Kieser M
PY  - 2022
JO  - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
DO  - 10.1016/j.jval.2022.05.015
UR  - https://doi.org/10.1016/j.jval.2022.05.015
ER  - 

APA

CA, B., J, K., & M, K. (2022). A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials-A Simulation Study.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. https://doi.org/10.1016/j.jval.2022.05.015

Source records